MicroRNAs作为药物性肝损伤生物标记物研究进展

doi:10.3969/j.issn.1672-5069.2023.05.040

Abstract

Gui Fenfen, Zhou Jiebin. Micro RNAs as biomarkers in patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2023, 26(5): 761-764.

[1] Xu HM, Chen Y, Xu J, et al. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol, 2012,18(41):5972-5978.
[2] Tran T, Lee WM. DILI: New insights into diagnosis and management. Curr Hepat Rep, 2013,12(1):53-58.
[3] Tarantino G, Di MMN, Capone D. Drug-induced liver injury: is it somehow foreseeable. World J Gastroenterol, 2009,15(23):2817-2833.
[4] Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology, 2008,245(3):194-205.
[5] Lindblom P, Rafter I, Copley C, et al. Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies. Arch Biochem Biophys, 2007,466(1):66-77.
[6] Mendrick DL, Daniels KK. Biomarkers of drug-induced adverse events. Expert Rev Clin Pharmacol, 2008,1(1):81-91.
[7] Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem, 2010,56(12):1830-1838.
[8] Doi Y, Kubo M, Yonemoto K, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring), 2007,15(7):1841-1850.
[9] Jung HJ, Suh Y. Circulating miRNAs in ageing and ageing-related diseases. J Genet Genomics, 2014,41(9):465-472.
[10] Collins RE, Cheng X. Structural and biochemical advances in mammalian RNAi. J Cell Biochem, 2006,99(5):1251-1266.
[11] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004,116(2):281-297.
[12] Koturbash I, Beland FA, Pogribny IP. Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants. Expert Opin Drug Metab Toxicol, 2012,8(5):597-606.
[13] Ward J, Bala S, Petrasek J, et al. Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study. World J Gastroenterol, 2012,18(22):2798-2804.
[14] Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem, 2010,56(11):1733-1741.
[15] Sempere LF, Freemantle S, Pitha-Rowe I, et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol, 2004,5(3):R13.
[16] Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). J Mol Cell Cardiol, 2016,94:107-121.
[17] Roderburg C, Benz F, Vargas CD, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int, 2015,35(4):1172-1184.
[18] Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature, 2000,408:86-89.
[19] Yoshioka W, Higashiyama W, Tohyama C. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol Sci, 2011,122(2):457-465.
[20] Fukushima T, Hamada Y, Yamada H, et al. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride--regulating role of micro-RNA for RNA expression. J Toxicol Sci, 2007,32(4):401-409.
[21] Dai BH, Geng L, Wang Y, et al. microRNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. Cell Death Dis, 2013,4:e604.
[22] Di LG, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol, 2014,9:287-314.
[23] Dahiya N, Atreya CD. MicroRNAs and major blood-borne infectious viral diseases. Microrna, 2014,2(3):212-218.
[24] Park SY, Jeong HJ, Yang WM, et al. Implications of microRNAs in the pathogenesis of diabetes. Arch Pharm Res, 2013,36(2):154-166.
[25] Dangwal S, Thum T. microRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol, 2014,54:185-203.
[26] Bandiera S, Pfeffer S, Baumert TF, et al. miR-122--a key factor and therapeutic target in liver disease. J Hepatol, 2015,62(2):448-457.
[27] Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One, 2014,9(12):e113651.
[28] Yamaura Y, Tatsumi N, Takagi S, et al. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin Biochem, 2017,50(18):1034-1039.
[29] Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A, 2009,106(11):4402-4407.
[30] Lewis AP, Jopling CL. Regulation and biological function of the liver-specific miR-122. Biochem Soc Trans, 2010,38(6):1553-1557.
[31] Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J Cell Biol, 2012,199(3):407-412.
[32] Park HK, Jo W, Choi HJ, et al. Time-course changes in the expression levels of miR-122, -155, and -21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci, 2016,17(1):45-51.
[33] Krauskopf J, Caiment F, Claessen SM, et al. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci, 2015,143(2):268-276.
[34] Starkey LPJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology, 2011,54(5):1767-1776.
[35] Dear JW, Antoine DJ, Starkey-Lewis P, et al. Early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br J Clin Pharmacol, 2014,77(5):904-905.
[36] Starkey LPJ, Merz M, Couttet P, et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther, 2012,92(3):291-293.
[37] Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One, 2012,7(5):e37395.
[38] Corsini A, Ganey P, Ju C, et al. Current challenges and controversies in drug-induced liver injury. Drug Saf, 2012,35(12):1099-1117.
[39] Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol, 2005,33(1):155-164.
[40] Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology, 2012,56(5):1946-1957.
[41] Yang X, Weng Z, Mendrick DL, et al. Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol Lett, 2014,225(3):401-406.
[42] Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol, 2011,13(4):423-433.
[43] Momen-Heravi F, Saha B, Kodys K, et al. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med, 2015,13:261.
[44] Yamaura Y, Nakajima M, Takagi S, et al. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One, 2012,7(2):e30250.
[45] Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A, 2014,111(33):12169-12174.
[46] Lardizábal MN, Nocito AL, Daniele SM, et al. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. PLoS One, 2012,7(5):e36323.
[47] Lardizábal MN, Nocito AL, Daniele SM, et al. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. PLoS One, 2012,7(5):e36323.
[48] Wang Y, Tang N, Hui T, et al. Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. J Appl Toxicol, 2013,33(11):1330-1336.

Micro RNAs as biomarkers in patients with drug-induced liver injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[2]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[3]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[4]	Cai Xin, Xin Chunhong, Niu Hongkai, et al. Changes of serum HIF-1α, Chemerin and adiponectin levels in patients with metabolic-associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(5): 654-657.
[5]	Li Ling, He Xiaoqi, Gao Yong, et al. Serum miR-21, Nrf2 and HO-1 level changes in pregnant women with drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(5): 662-665.
[6]	Mo Junqiao, Lin Jing, Yang Li. Improvement of liver function tests by silibinin and polyene phosphatidylcholine combination therapy in patients with anti-tuberculosis drugs-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(5): 666-669.
[7]	Pei Sujuan, Guo Jinhui, Wei Xiaoxia. Common medicines and influencing factors on severity of liver injury in hospital stay patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(5): 670-673.
[8]	Chen Yuan, Ge Shang, Wang Shiyu. Diagnostic performance of multi-slice spiral CT and MRI dynamic enhancement in patients with hypervascular intrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2023, 26(5): 718-721.
[9]	Zhang Yun, Yu Yixing, Zhao Weifeng. Clinical features of patients with hepatic perivascular epithelioid cell tumor: An analysis of 5 cases [J]. Journal of Practical Hepatology, 2023, 26(5): 722-725.
[10]	Zhu Zhimin, Li Hua, Chen Yi, et al. DCE-MRI quantitative parameters in differentiating malignant from benign small intrahepatic space-occupying lesions [J]. Journal of Practical Hepatology, 2023, 26(5): 726-729.
[11]	Xu Qiao, Li Yajuan, Chen Hui. Application of apparent diffusion coefficient by diffusion weighted imaging of MR in the differentiate diagnosis of patients with hepatic cystic echinococcosis and simple hepatic cyst [J]. Journal of Practical Hepatology, 2023, 26(5): 734-737.
[12]	Guan Ruilian, Sun Chuanchuan, Lin Tulian, et al. Congenital hepatic arteriovenous fistula in neonates: A report of two cases and literature review [J]. Journal of Practical Hepatology, 2023, 26(5): 757-760.
[13]	Shi Ying, Lyu Yongyan, Yang Zengdi, et al. Evaluation of significant liver fibrosis by ultrasonic shear wave elastography in rats with carbon tetrachloride-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(4): 476-479.
[14]	Zhou Keli, Lyu Xiaoli, Zhou Yang, et al. Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(4): 480-483.
[15]	Hu Lingxi, An Xinyu, Li Mei, et al. Diagnostic performance of ultrasound attenuation parameters in predicting fatty liver diseases in individuals at physical examination [J]. Journal of Practical Hepatology, 2023, 26(4): 488-491.